Shmuel Yaccoby, PhD

Research Program: Cancer Biology Faculty Rank: Professor Campus: University of Arkansas for Medical Sciences College: College of Medicine Department: Internal Medicine

Cancer Research Interest

• Disease Site Focus: Multiple Myeloma
• Research Focus Area: Health Disparities, Prevention, Treatment, Informatics, Detection, Diagnosis/ Prognosis
• Type of Research: Basic
• Research Interest Statement: Pathogenesis of multiple myeloma, tumor microenvironment, bone marrow mesenchymal stem cells, and tumor initiating cells.

Contact Information

• Email Address: YACCOBYSHMUEL@UAMS.EDU
• Profiles Research Networking Software: View Profile

Active Grants

• US Department of Defense – W81XWH2110601
  “Role of Novel Myeloma Subpopulations”
  Principal Investigator
  09/30/21 – 09/29/24

Publications

• Mikulasova A, Kent D, Trevisan-Herraz M, [et al., including Yaccoby S]. Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers. Genome research. 2021. PMID: 34933939.
• Schinke CD, Boerma M, Bird JT, [et al., including Yaccoby S]. PHF19 inhibition as a therapeutic target in multiple myeloma. Current research in translational medicine. 2021 69(3):103290. PMID: 33894670.
• Mikulasova A, Ashby C, Tytarenko RG, [et al., including Yaccoby S]. Microhomology-mediated end joining drives complex rearrangements and over expression of MYC and PVT1 in multiple myeloma. Haematologica. 2019. PMID: 31221783.
• Mehdi SJ, Johnson SK, Epstein J, [et al., including Yaccoby S]. Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes. British journal of haematology. 2019 184(4):578-593. PMID: 30408155. PMCID: PMC6361704.
• Rasche L, Angtuaco EJ, Alpe TL, [et al., including Yaccoby S]. The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. Blood. 2018 132(1):59-66. PMID: 29784643. PMCID: PMC6034645.
• Schinke C, Qu P, Mehdi SJ, [et al., including Yaccoby S]. The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 24(12):2913-2919. PMID: 29563136.
• Yaccoby S. Two States of Myeloma Stem Cells. Clinical lymphoma, myeloma & leukemia. 2018 18(1):38-43. PMID: 29066162.
• Thanendrarajan S, Tian E, Qu P, [et al., including Yaccoby S]. The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma. Haematologica. 2017 102(9):e364-e367. PMID: 28550191. PMCID: PMC5685226.
• Hoering A, Wang H, Carlton V, [et al., including Yaccoby S]. The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype. Haematologica. 2017 102(8):e313-e316. PMID: 28522572. PMCID: PMC5541885.
• Rasche L, Angtuaco E, McDonald JE, [et al., including Yaccoby S]. Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood. 2017 130(1):30-34. PMID: 28432222. PMCID: PMC5501152.
• Jethava YS, Mitchell A, Epstein J, [et al., including Yaccoby S]. Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 23(11):2665-2672. PMID: 27810902. PMCID: PMC6080620.
• Mohan M, Samant RS, Yoon D, [et al., including Yaccoby S]. Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2017 32(6):1261-1266. PMID: 28240368. PMCID: PMC5466479.
• Jethava Y, Mitchell A, Zangari M, [et al., including Yaccoby S]. Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma. Blood cancer journal. 2016 6:e471. PMID: 27635734. PMCID: PMC5056975.
• Jethava Y, Mitchell A, Zangari M, [et al., including Yaccoby S]. Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma. Blood cancer journal. 2016 6(7):e453. PMID: 27471869. PMCID: PMC5030385.